Updates
Developments
A running, dated record of what is actually moving in the FDA’s review of these peptides — each entry tied to primary filings and major reporting, with a plain-English read on what it changes. Newest first.
July 24, 2026
Day 2: Epitalon and Semax recommended, Emideltide rejected — six of seven clear the committee
On the meeting’s closing day the committee recommended Epitalon for insomnia, 7–4 with one abstention, and Semax for cerebral ischemia, migraine and trigeminal neuralgia, 8–5 with one abstention. It declined to recommend Emideltide (DSIP) for opioid withdrawal, chronic insomnia and narcolepsy, which failed 6–7 — the single substance of the seven to be turned down, and the panel’s only break from a two-day pattern of voting against the FDA’s own review staff. The rejection carries an irony: Emideltide has the longest human research record of the group, with published trials going back to 1981, but the agency’s reviewers judged those studies small, poorly controlled and contradictory, and flagged a theoretical dependence risk in the way the peptide acts on endorphin release. One member who had backed every earlier substance broke with the majority over what he described as dangerous downstream consequences. Semax’s supporters argued it has more evidence behind it than most of the group because it is approved for clinical use in Russia; FDA staff still found that evidence insufficient.
What it means: Six recommendations, zero authorisations. Every favourable vote is advisory — the FDA now decides whether to open notice-and-comment rulemaking, which practitioners put at roughly eight to twelve months before a 503A pharmacy would have unambiguous authority to compound any of these. Emideltide’s rejection is not a ban either: it stays exactly where it has been since April, off Category 2 and not on Category 1. Nothing at a compounding pharmacy changes today for any of the seven.
July 23, 2026
Day 1: the committee recommends all four peptides — against the FDA’s own review
The Pharmacy Compounding Advisory Committee recommended all four of Thursday’s substances for the 503A bulks list. BPC-157, KPV and TB-500 each carried 8–6 with one abstention; MOTS-c carried 7–5 with two abstentions. Each substance drew separate votes on its free base and acetate forms. The recommendations run against the FDA’s own review staff, whose briefing documents concluded that the evidence supported adding none of the seven. Members voting yes leaned on the gray market — one described a patient arriving with research-grade material that turned out to be adulterated — while members voting no warned that a place on the FDA’s list would read to the public as an endorsement the human data cannot support. Emideltide (DSIP), Epitalon and Semax are before the committee on Friday.
What it means: A recommendation is not authorisation. The vote is advisory — the FDA decides whether to open rulemaking, and no pharmacy may compound these peptides until a final rule is in place. One detail the headlines miss: each peptide was judged against a narrow indication — BPC-157 for ulcerative colitis, not tendon or joint repair — yet if the FDA reclassifies them, prescribers would have discretion to go outside those indications.
July 17, 2026
Pre-vote check: agenda and briefing documents confirmed
With the committee vote six days out, we re-checked the docket against the FDA’s live agenda. The July 23–24 meeting is confirmed at the FDA’s White Oak Campus, the agenda is final, and all seven of the FDA’s scientific briefing documents — plus the introduction — are now posted on the FDA’s meeting page. For the record, the committee is reviewing each peptide for the specific uses the FDA evaluated: BPC-157 (ulcerative colitis); KPV (wound healing and inflammatory conditions); TB-500 (wound healing); MOTS-c (obesity and osteoporosis); Emideltide/DSIP (opioid withdrawal, chronic insomnia, and narcolepsy); Semax (cerebral ischemia, migraine, and trigeminal neuralgia); Epitalon (insomnia).
What it means: Nothing has changed in the substance of the review since the briefing documents were released. The vote remains on for July 23–24, the FDA staff’s skeptical assessment stands, and any recommendation would still require FDA rulemaking before a pharmacy could compound these peptides.
July 1, 2026
FDA review staff recommend against all seven peptides
Ahead of the July 23–24 meeting, the FDA released its briefing materials, and the agency’s own review staff concluded that the available evidence does not support adding the seven peptides to the 503A bulks list — pointing to limited human data and unresolved safety questions for several of the substances. The assessment is notable because it runs against the publicly stated position of HHS Secretary Robert F. Kennedy Jr., who has favored broader peptide access.
What it means: PCAC is advisory. The committee weighs this staff review alongside the nominators’ presentations and public comment, then votes on non-binding recommendations; the FDA decides afterward whether to begin rulemaking. A staff “no” does not settle the outcome, but it raises the bar and sets up a visible split between FDA scientists and department leadership.
June 29, 2026
Advisory committee seated — and its membership draws scrutiny
The FDA named the members who will sit for the July meeting, bringing the panel to 14. Reporting noted that roughly half of the seated members have professional ties to businesses or clinics involved in peptide therapies, prompting conflict-of-interest questions; HHS said every member completed the same ethics review required of all advisory-committee members.
What it means: This resolves the earlier open question of whether the committee would be large enough to vote. It also makes the panel’s composition — and how it weighs the FDA staff review against nominator data — a storyline in its own right heading into the vote.
April 16, 2026
The meeting is formally noticed
The FDA published a Federal Register notice scheduling the PCAC meeting for July 23–24, 2026 and opening a public docket (FDA-2025-N-6895). Day 1 covers BPC-157, KPV, TB-500 and MOTS-c; Day 2 covers Emideltide (DSIP), Semax and Epitalon. A separate meeting before the end of February 2027 is slated to review five more substances, including GHK-Cu and Melanotan II.
What it means: This set the agenda and the public-comment timeline running up to the vote — and confirmed that GHK-Cu and Melanotan II are in the later batch, so their status does not change on July 23–24.
April 15, 2026
The peptides leave Category 2 — but not because they were cleared
The FDA noticed the removal of the same seven peptides from 503A Category 2, effective after seven days. The removal followed the withdrawal of the underlying nominations — by LDT Health Solutions (a consulting firm representing the International Peptide Society) and the Wells Pharmacy Network — not any safety finding. The FDA said it would review the substances at PCAC regardless.
What it means: Leaving Category 2 is not the same as moving to Category 1. It does not authorize compounding and does not grant enforcement discretion; the substances sit in a regulatory gap pending the July review. This is the single most-misreported point in the whole story — “off Category 2” has been widely miswritten as “legal again.”
The Compounding Brief
Get the next update by email
We email when a peptide’s status actually moves — committee votes, briefing documents, final rules — plus the occasional licensed-access update. No hype, no filler.
Free. Unsubscribe anytime. We never share your email. Not medical advice.